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INTRODUCTION
Organ transplantation, particularly bone marrow trans-
plantation (BMT), is associated with profound immunosup-
pression and thus increases the risk of complicated varicella
zoster virus (VZV) infections [1-5]. VZV infection remains
the most common viral disease in the late post-transplanta-
tion period, with a reported incidence rate ranging between
17% and 50% [1-3,5]. 
VZV infections after BMT can present as a primary
infection, but most of these infections are due to re a c t i v a-
tion of latent virus, presenting as either localized or dis-
seminated herpes zoster. Generally, the infection re m a i n s
confined to skin, although visceral involvement can occur
[6,7]. In immunocompromised patients, lesions are slower
to heal and more apt to become secondarily infected.
Cutaneous and visceral dissemination can occur and is
associated with serious morbidity and mortality [8-12].
S e ropositive patients undergoing BMT may also develop
an atypical varicella-like illness associated with generalized
skin lesions [13-15].
The morbidity associated with VZV reactivation and
post-herpetic neuralgia results in an impairment of the quali t y
of life, which may also lead to an increase in transplantation-
related costs. In this re t rospective study, we reviewed the
incidence and onset of VZV infections, as well as their
c l i n ical outcome, risk factors, and impact on morbidity and
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ABSTRACT
Reactivation of varicella zoster virus (VZV) is a common event in patients undergoing allogeneic bone marro w
transplantation (BMT) and may lead to life-threatening complications. We re t rospectively analyzed the incidence,
clinical outcome, and risk factors for VZV infections occurring within the first 5 years of transplantation in 100 con-
secutive adults undergoing allogeneic BMT between 1992 and 1997. Forty-one patients (41%) developed VZV
reactivation a median of 227 days (range 45-346 days) post-transplantation. Twelve percent of VZV re a c t i v a t i o n
o c c u rred in the first 100 days and 88% within the first 24 months. Among those who survived for 2 or more years
after transplantation (n = 47), 59% developed VZV infection. Forty percent of patients with VZV re a c t i v a t i o n
re q u i red admission with a mean hospital stay of 7.2 days. Two patients developed encephalitis, and 1 died despite
antiviral therapy. The most frequent complications were post-herpetic neuralgia and peripheral neuropathy (68%).
Thoracic dermatomal zoster re p resented 41% of the infections; disseminated cutaneous involvement was observ e d
in 17% of patients. No clinical or epidemiologic risk factors were associated with re c u rrence. Administration of gan-
ciclovir for prevention of cytomegalovirus infection delayed the onset of VZV infection beyond 4 months (P = . 0 6 ) .
In a further subset analysis, patients with a limited chronic graft-versus-host disease (GVHD) had a lower estimated
incidence of VZV reactivation compared with those with extensive chronic GVHD (P = .11). We conclude that com-
plications from reactivation of VZV infection are common and associated with considerable morbidity and mort a l i t y
in patients undergoing allogeneic BMT.
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m o rt a lity in 100 consecutive patients undergoing allogeneic
BMT at a single institution.
PATIENTS AND METHODS
Patient P o p u l a t i o n
One hundred consecutive patients who underwent an
allogeneic BMT from matched siblings or unrelated donors
between 1992 and 1997 at the New England Medical Center
w e re re t rospectively analyzed. Medical re c o rds were re v i e w e d
for the following variables: patient demographics, diagnosis,
type of BMT, conditioning regimen, pretransplantation radia-
tion, pretransplantation serology for cytomegalovirus (CMV),
herpes simplex virus (HSV) and VZV, graft-versus-host dis-
ease (GVHD) prophylaxis, type and severity of GVHD,
antiviral prophylaxis, time to development of VZV infection,
p resence and severity of GVHD before diagnosis of VZV
infection, details and duration of treatment for VZV infec-
tion, extent of VZV infection, complete blood counts at the
time of VZV infection, secondary infections encountere d
within 30 days of resolution of VZV infection, response to
antiviral therapy, rate of hospitalization, complications re l a t e d
to viral infection, mortality rate, and VZV- f ree interv a l .
The diagnosis of VZV reactivation was established by
clinical findings including vesicular eruption on an ery t h e-
matous base within a dermatome or a generalized cutaneous
distribution. In equivocal cases, clinical diagnosis was con-
f i rmed by viral culture, cytologic review of skin lesions
(Tzanck smear), or skin biopsy.
P re p a r a t o r y Regimen
Patients undergoing allogeneic BMT received cyclophos-
phamide (60 mg/kg per day × 2 days) combined with either
total body irradiation (TBI) (200 cGy bid × 3 days) or busul-
fan (1 mg/kg every 6 hours × 4 days). Patients with re l a p s e d ,
re f r a c t o ry, or secondary leukemia received etoposide (VP16)
(30 mg/kg × 1 day) in addition to the previously described
regimen. In patients with aplastic anemia, TBI was re p l a c e d
with total lymphoid irradiation (TLI) at a dose of 750 cGy
given 24 hours before marrow infusion. All patients with
c h ronic myelogenous leukemia received splenic irradiation at
a dose of 500 cGy administered in 5 fractions before initiation
of the conditioning regimen. Patients with multiple myeloma
received melphalan (140 mg/m2 × 1 day) combined with TBI
(200 cGy bid × 3 days) as the pre p a r a t o ry re g i m e n .
S u p p o rt i v e Therapy
All patients undergoing allogeneic BMT re c e i v e d
weekly intravenous (IV) immunoglobulin (0.5 g/kg) in the
first 8 weeks, with gradual tapering and discontinuation at
4 months. Cipro floxacin (500 mg orally every 12 hours) was
s t a rted routinely for infection prophylaxis before day –4.
Acyclovir prophylaxis (200 mg orally 5 × daily or 5 mg/kg
IV every 8 hours) was initiated on day –1 and continued
until engraftment. After documentation of engraftment, all
patients with positive CMV serology results or patients with
negative CMV serology results receiving hematopoietic
stem cells from CMV- s e ropositive donors (n = 54) were
given prophylactic ganciclovir infusions at 5 mg/kg per day
a d m i n i s t e red 3 or 5 times weekly as tolerated until day
+100. All patients received oral topical antifungal pro p h y-
laxis with clotrimazole troches or nystatin and were housed
in high-efficiency particulate air–filtered rooms to minimize
the risk of invasive fungal infections.
G r a f t - V ersus-Host Disease Pr o p hy l a x i s
All patients undergoing allogeneic BMT from related or
u n related donors received adjusted-dose continuous-infusion
cyclosporin A (CSA), ranging between 2.0 and 5.5 mg/kg per
day and administered between day –1 and +50 to keep the
CSA levels between 475 and 525 ng/mL as determined by
f l u o rescence polarization assay. Patients were switched to
oral CSA on day +50 at a dosage of 5 mg/kg every 12 hours
and tapered to day +180. These patients also received 2 or
3 doses of methotrexate at 15 mg/m2 IV on day +1 and
10 m g / m2 IV on days +3 and day +6 (omitted in patients
experiencing severe mucositis) for prevention of GVHD.
When patients developed grade II or higher GVHD despite
the prophylactic regimen, they were treated with IV methyl-
p rednisolone at doses ranging between 20 and 200 mg/day.
Statistical Anal y s i s
Patients who remained free of VZV infection after
a l l ogeneic BMT were censored at the time of their last fol-
low-up or death. The incidence of VZV reactivation was
d e t e rmined using the nonparametric Kaplan-Meier test
[16]. Assessments of differences in VZV incidence between
the risk groups were made by univariate analysis using the
log rank test. The analysis of the effect of the prophylactic
antiviral regimen on incidence of VZV reactivation during
the early post-transplantation period (first 6 months) was
performed using the log rank test. In the multivariate analy-
sis, a Cox pro p o rtional hazards model was used to define
independent risk factors with the StatView 5.0 statistical
software (SAS Institute Inc, Cary, NC).
RESULTS
Frequency and Onset of VZV Inf e c t i o n
Of 100 consecutive patients, 84 survived beyond day +1 0 0 ,
with a median follow-up of 2 years (0-84+ months). VZV
infection occurred in 41% of the patients. Most infections
(88%) occurred within the first 24 months, with a median
i n t e rval of 227 days (45 days to 3.7 years) from the day of
transplantation. The estimated VZV- f ree incidence was 64%
at 5 years after allogeneic BMT (Figure 1). Although 68% of
VZV infections developed within 1 year after transplantation,
only 12% occurred within the first 3 months. Among
49 patients who were followed up for more than 2 years after
transplantation, 59% developed VZV re a c t i v a t i o n .
Clinical and Epidemiologic Characteristics
The clinical presentation of patients with VZV reactiva-
tion is summarized in Table 1. Most VZV infections
(80.4%) showed a dermatomal distribution. All patients who
developed VZV disease were seropositive for VZV before
B M T. Twenty-two patients (53.6%) had complicated VZV
infections, including disseminated or varicella-like cuta-
neous involvement in more than 2 dermatomes in 7 patients
(17%) and visceral involvement in 3 patients (7%). Tw o
patients developed VZV encephalitis; one expired as a sec-
o n d a ry result of pro g ressive disease despite IV acyclovir
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t h e r a p y, whereas the other patient re c o v e red completely
after IV acyclovir treatment. 
The median age, seropositivity for CMV, presence of
acute GVHD, conditioning regimen, and presence of
leukemia were similar among the patient groups who did or
did not develop VZV reactivation. The clinical and epi-
demiologic characteristics of the cohort of transplant recipi-
ents are listed in Table 2.
Analysis was perf o rmed for clinical risk factors that
might correlate with prolonged pain. Older age and a cranial
location of reactivation were associated with prolonged pain
in the univariate analyses (P = .03 and P = .04, respectively).
Timing of reactivation did not correlate with pro l o n g e d
post-herpetic neuralgia (P = .20) or with earlier-onset dis-
ease (P = .23). Cranial and disseminated skin involvement
was associated with more common complications. We were
unable to demonstrate any correlation between complicated
zoster and survival, diagnosis, relapse, conditioning re g i-
mens, splenic irradiation or TBI, acute or chronic GVHD,
or serologic status for CMV and HSV in our series.
Treatment and Outcome
All patients except the one who died with encephalitis
(97.5%) responded to treatment with an antiviral agent.
Although all dermatomal zoster episodes healed, 53.6% of
patients experienced clinically significant complications.
The most common complication was post-herpetic neural-
gia (41%), defined as persistence of re q u i rement of analge-
sia for more than 4 weeks after viral reactivation. Patients
t reated as outpatients received oral antiviral agents consist-
ing of either acyclovir or famciclovir with a mean duration
of treatment of 13.2 ± 3.7 days (range 7-25). Of the 41
patients with VZV reactivation, 18 (44%) re q u i red hospi-
talization for IV therapy, hydration, and management of
pain. The median hospital stay was 7 ± 0.73 days. The
majority of patients admitted received IV acyclovir during
the first 3-7 days followed by oral acyclovir or famciclovir.
T h ree patients developed bacterial or viral superinfection
within 30 days after the VZV reactivation, including pneu-
mococcal pneumonia, staphylococcal cellulitis, and genital
HSV infection.
A n a l ysis of Risk Factors for VZV Reactivation
Clinical factors were examined, with analysis of the
VZV incidence to identify the possible impact on the devel-
opment and onset of VZV infection following allogeneic
BMT (Table 3). Age, sex, donor or recipient sero p o s i t i v i t y
for CMV or VZV, and presence of acute or chronic GVHD
were not found to be significantly associated with a higher
rate of VZV disease. 
Patients who received acyclovir prophylaxis for only
4 weeks and those who also continued to receive gancic l o v i r
Figure 1. Estimated incidence of varicella zoster virus (VZV) reactivation at 5 years in 100 consecutive allogeneic bone marrow transplant recipients.
Table 1. Location of VZV Infections and Complications Secondary to VZV
Reactivation Encountered During the Post-Transplantation Period*
% of all VZV
Number R e a c t i v a t i o n s
Total evaluable patients 41 100
Clinical presentation †
Thoracic 17 41







Postherpetic neuralgia and scarring 17 41
Abdominal pain 3 7
CNS involvement 2 5
Ocular disease 1 2
Peripheral neuropathy 1 2
No. of patients with complications 22 54
Total no. of complications 24
*CNS indicates central nervous system.
†One patient had involvement in 2 dermatomes (sacral and thoracic).
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for CMV prophylaxis until day +100 after the acyclovir
p rophylaxis had similar rates of overall VZV re a c t i v a t i o n
(41% and 43%, respectively). In the subset of patients who
received prolonged antiviral prophylaxis with ganciclovir
(5 mg/kg per day IV 3 times per week to day 100), none
developed VZV reactivation in the first 120 days after allo-
geneic BMT. In contrast, 7 patients receiving short - c o u r s e
antiviral prophylaxis with acyclovir alone developed VZV
reactivation during the same period (incidence of VZV:
19.4%, 95% CI 6.5%-32.3%), suggesting a delay in onset
of VZV infection secondary to ganciclovir use between
engraftment date until day +1 0 0 .
Patients with VZV reactivation were analyzed with
respect to the timing of viral reactivation. Only 11% of
patients who received ganciclovir prophylaxis developed the
VZV reactivation in the first 6 months, compared with 23%
in patients who received short - t e rm acyclovir (P = . 0 6 )
( F i g u re 2). As expected, VZV-free survival at 5 years did not
demonstrate any benefit for 100 days of ganciclovir com-
p a red with no antiviral prophylaxis (P = .43). Of the
8 patients who received prolonged oral antiviral prophylaxis
beyond day +100 with either acyclovir or famciclovir to pre-
vent re c u rrent oral HSV infections complicating chro n i c
oral GVHD, none developed VZV reactivation.
P resence and type of limited chronic GVHD on the
VZV reactivation rates were also analyzed in patients
s u rv ivi ng beyond day +100.  Pat ients with limited
c h ronic GVHD had a trend toward a lower incidence of
VZV disease compared with those with extensive GVHD
(P = .11) (Figure 3). 
DISCUSSION
Both allogeneic and autologous BMT patients have an
i n c reased incidence of VZV infections [1-5]. The pro f o u n d
i m m u n o s u p p ression accompanying BMT results in a high
incidence of viral infections [17]. Several series of VZV infec-
tions have been re p o rted in the literature [1,2,4], but most of
these studies have combined patients undergoing autologous
with those undergoing allogeneic BMTs. In a series re p o rt e d
f rom Seattle [2,3] and Minnesota [5], the incidence of VZV
reactivation among allogeneic BMT patients was between
30% and 46%, exceeding the rates observed in renal trans-
plant (3%-10%) and heart transplant recipients (20%) [18].
In all re p o rts, serious VZV infections primarily occurre d
within the first 9 months after transplantation [1-5].
In our series of 100 consecutive patients underg o i n g
allogeneic BMT, the estimated reactivation rate at 5 years
was 63% (Figure 1). Although not entirely understood, the
relatively high incidence of VZV reactivation in our series
may be secondary to the absence of pediatric patients, a rel-
atively higher median age (38 years), the use of TBI in most
patients (80%), and administration of a relatively more
intensive immunosuppressive regimen for acute GVHD
p rophylaxis. Most of the VZV infections (85%) occurre d
within the first 2 years after transplantation. Late-onset
post-transplantation VZV infection most often presented as
uncomplicated dermatomal zoster. Only 25% (4/16) of the
serious VZV infections, namely, disseminated disease,
o c ular/cranial involvement, and involvement of more than
1 dermatome, were encountered beyond the first post-trans-
plantation year. No visceral infections occurred in patients
more than 8 months after transplantation.
Various risk factors, including age, sex, underlying dis-
ease, conditioning regimen, pretransplantation serology, and
GVHD status, have been studied to define certain patient
groups with a high risk of VZV reactivation. Of these, age
(≥10 years) [2,5], pretransplantation radiation in the form of
TBI or TLI [5,19], presence of acute or chronic GVHD [2],
the use of post-transplantation antithymocyte globulin [2],
and an underlying diagnosis other than chronic myeloge-
nous leukemia [2] have been reported to be associated with a
higher incidence of VZV reactivation.
In examining the rates of VZV reactivation comparing
patients with limited GVHD and those with extensive
c h ronic GVHD, we noted a trend toward greater re a c t i v a-
tion rates in those with extensive GVHD. Pre s u m a b l y, those
with more extensive  chronic GVHD re q u i re gre a t e r
i m m u n o s u p p ression, resulting in somewhat higher rates of
re a c t i v a t i o n .
Additional subgroup analysis demonstrated diff e re n t
reactivation rates in patients who received antiviral
Table 2. Clinical and Epidemiologic Characteristics of a Cohort of Allogeneic
Bone Marrow Transplant Recipients With Respect to VZV Occurrence*
VZV No VZV
Reactivation Reactivation
Risk Factor n = 41 n = 59
Median age years (range) 39 (16-57) 36 (13-57)
Male patients 29 (70.7%) 31 (52.5)
Pre-BMT diagnosis
Leukemia 35 (85.3%) 44 (74.5)
Lymphoma 3 (7.3%) 5 (8.5%)
Other malignancy 1 (2.4%) 5 (8.5)
Nontumor 2 (4.9%) 5 (8.5%)
Type of BMT
Related 40 (97.6%) 50 (84.7%)
Matched unrelated 1 (2.3%) 9 (15.3%)
Conditioning regimen
With TBI 35 (85.4%) 45 (76.2%)
With splenic radiation 15 (36.5%) 18 (30.5%)
Recipient viral serology
CMV-positive 17 (41.5%) 26 (44.1%)
HSV-positive 26 (63.4%) 35 (59.3%)
VZV-positive 39 (95.1%) 54 (91.5%)
Antiviral prophylaxis †
Acyclovir 28 days 18 (43.9%) 26 (44.1%)
Ganciclovir 100 days 23 (56.1%) 31 (52.5%)
Graft-versus-host disease
Acute ‡
Grade 0, 1 33 (80.5%) 46 (78.0%)
Grades II-IV 8 (19.5%) 12 (22.0%)
Chronic §
Limited 13 (31.7%) 18 (30.5%)
Extensive 8 (19.5%) 7 (11.9%)
*BMT indicates bone marrow transplantation; CMV, cytomegalovirus; HSV,
herpes simplex virus; TBI, total body irradiation; VZV, varicella zoster virus.
†Two patients expired within 3 weeks after bone marrow transplantation.
‡One patient expired within 7 days after bone marrow transplantation.
§Only 84 patients had risk of chronic graft-versus-host disease, because 16
patients expired before day +100.
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p rophylaxis. Those who received ganciclovir for CMV pre-
vention were noted to have a strong trend toward delayed
onset of VZV reactivation, although this effect waned after 8
months. More o v e r, among those who received pro l o n g e d
p rophylaxis to prevent HSV reactivation with complicated
mucositis, none developed VZV re a c t i v a t i o n .
The role of post-transplantation antiviral prophylaxis in
p revention of VZV reactivation is unclear. In some series,
the prophylactic use of acyclovir up to 6 months after trans-
plantation appears to be ineffective in reducing the overall
VZV reactivation rate; disease onset is delayed beyond the
period of prophylaxis [20-22]. Development of a more effec-
tive prevention strategy, particularly in those targeted risk
g roups expected to have high VZV reactivation rates or a
m o re complicated course, may be necessary. Possibly, pro-
longed oral antiviral prophylaxis for at least 2 years after
Figure 2. Impact of duration of antiviral prophylaxis on onset of VZV reactivation during the early post-transplantation period. P indicates probability of VZV
reactivation, log rank test; ACV, acyclovir; GCV, ganciclovir; VZV, varicella zoster.
Figure 3. Comparison of estimated incidence of varicella zoster virus (VZV) reactivation at 5 years in patients with limited chronic graft-versus-host disease
(CGVHD) versus those with extensive CGVHD. P indicates  probability of VZV reactivation, log rank test.
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transplantation may reduce the high incidence of VZV
infections in patients undergoing allogeneic BMT, allowing
patients to re s t o re their cellular immunity. However, the
agent of choice, dosage, schedule of administration, and
duration for such prophylaxis and cost-effectiveness remain
unknown. The potential of VZV resistance to antiviral
agents and delayed reestablishment of effective cellular
immunity against this particular virus are also factors that
may affect any potential preventive antiviral strategies. Effi-
cacy of prolonged antiviral prophylaxis in delaying the onset
of VZV reactivation and paucity of VZV infections in
patients surviving beyond 2 years emphasize the need for a
randomized trial to test the efficacy of prolonged oral antivi-
ral prophylaxis along with efforts to restore the recovery of
cellular immunity to be able to reduce the overall incidence
of VZV infection in patients undergoing allogeneic BMT.
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Table 3. Comparison of VZV-Free Survival Between Risk Groups*
VZV P value
No. of Reactiviation (Log Rank
Patients % (95% CI) Test)
Age at BMT
≤45 73 58 (41, 74)
>45 27 79 (48, 100) .43
Sex
Male 60 73 (54, 96)
Female 40 48 (25, 74) .13
Type of allogeneic BMT
Allogeneic-related 90 63 (49, 78)
Matched-unrelated (MUD) 10 25 (0, 67) .35
Pre-BMT diagnosis
Leukemia 79 68 (52, 84)
Other 21 38 (4, 62) .37
Conditioning regimen
TBI-based 80 66 (51, 81)
Non–TBI-based 20 38 (14, 62) .43
Splenic radiation
Yes 33 72 (44, 99)
No 67 61 (43, 78) .80
Acute GVHD
None 40 56 (34, 72)
II and III 19 77 (17, 100) 72
I 39 60 (38, 82)
Chronic GVHD
Limited 31 52 (29, 75) .18
Extensive 15 62 (34, 90)
None 32 71 (51, 91)
Antiviral prophylaxis
ACV, until day +30 44 78 (54, 100)
GCV, until day +100 54 53 (37, 68) .43 
*ACV indicates acyclovir; BMT, bone marrow transplantation; GCV, ganci-
clovir, GVHD, graft-versus-host disease; TBI, total body irradiation; VZV,
varicella zoster virus.
